Cigna to cover Cambridge Heart's MTWA test
Cambridge Heart (Bedford, Massachusetts) said that Cigna HealthCare, a provider of healthcare benefits covering more than 12 million Americans, has revised its coverage position on Microvolt T Wave Alternans (MTWA) testing, agreeing to make it a covered benefit for its beneficiaries. The coverage position now states: “CIGNA HealthCare covers microvolt T-wave alternans testing as a method to identify risk of ventricular arrhythmias and sudden cardiac death for patients who meet criteria for implantable cardioverter defibrillator placement.”
“We are very pleased that after reviewing all of the published literature on Cambridge Heart's system . . . Cigna has recognized the benefit that MTWA can provide to their beneficiaries,” said David Chazanovitz, president and CEO of Cambridge Heart. “The utilization of our diagnostic test in patients eligible for implantable defibrillator therapy is becoming more and more important as physicians work to provide the most appropriate individualized care for their patients.”
Cambridge Heart makes products for the noninvasive diagnosis of cardiac disease. The Cambridge Heart Microvolt T-Wave Alternans Test measures T-wave alternans, extremely subtle beat-to-beat fluctuations in a person's heartbeat. Extensive clinical research has shown that patients with symptoms of or, who are at risk of, life threatening arrhythmias who test positive for T-wave alternans are at significant risk for subsequent sudden cardiac events including sudden death, while those who test negative are at minimal risk.